Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 1 day agoScore70
Body · original
Overall survival from phIII postMONARCH trial of abemaciclib + fulvestrant v placebo + fulv for HR+ HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy https://www.annalsofoncology.org/article/S0923-7534%2826%2908075-0/fulltext #ESMO26 @OncoAlert @KalinskyKevin @Annals_Oncology
126 views · 4 likes · 4 reposts · 0 replies
Conference abstracts
1ROmatched by Rapid oral 1: Breast cancer, advanced stage
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgSource: Stephanie Graff, MD, FACP, FASCO · x.com